Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1984-3-7
|
| pubmed:abstractText |
CSF levels of GABA were investigated in a group of Parkinson patients without drug treatment and a group of Parkinson patients under treatment with L-DOPA or anticholinergics. Probenecid results in an elevation of CSF GABA levels in healthy persons. The results indicate a significant decrease of GABA levels in CSF in untreated Parkinson patients. Parkinson patients treated with L-DOPA or anticholinergics show nearly normal CSF GABA levels. This may suggest that the altered GABA function in Parkinson's disease is secondary to changes in the dopamine system.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0091-3952
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
40
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
427-30
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading | |
| pubmed:year |
1984
|
| pubmed:articleTitle |
CSF GABA levels in Parkinson's disease.
|
| pubmed:publicationType |
Journal Article
|